OnKure Therapeutics, Inc. (NASDAQ:OKUR)
| Market Cap | $109.36M-1.8% |
| Revenue (ttm) | $0 |
| Net Income | -$61.85M+23.8% |
| EPS | -$2.77+54.3% |
| Shares Out | 40.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 195,211 |
| Open | $2.75 |
| Previous Close | $2.76 |
| Day's Range | $2.68 - $2.79 |
| 52-Week Range | $2.01 - $5.38 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | $14.00(+418.52%) |
| Earnings Date | Mar 11, 2027 |
About OKUR
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 11, 2027Earnings report
$OKUR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in OKUR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OKUR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OKUR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New OKUR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OKUR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OKUR
| VTIVanguard Morningstar Total Stock Market ETF | $2.38M |
| IWMiShares Russell 2000 ETF | $1.58M |
| VXFVanguard Extended Market ETF | $801.00K |
| IWNiShares Russell 2000 Value ETF | $614.18K |
| VTWOVanguard Russell 2000 ETF | $408.51K |
| TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | $365.59K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from OKUR’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
